Ann: Investigators Meeting Completed for BTX 1204 Phase 2 Study, page-7

Interesting is an understatement. Firstly our product could be superior to Eucrisa and in that case we have a monster on our hands. Secondly Pfizer paid way over the odds but that was another time. I would be happy with one tenth of that however I am sure Matt and his team would want more considering the amazing billion dollar industies - note plural for acne and atopic dermatitis. Sit back a little and condider the psoriasis angle here. The mind does crazy things but all of us need to keep a level head in terms of numbers. BOT is on well defined tracks made by the FDA and we will continue to ride them. The train has left the station but the gradient is a little steep right now. I want us to ride into Mayfair and then collect two hundred dollars.

The rise in the share price has been sniffed out by the in crowd but I am glad it has merit. The wait will not be long for us considering how slow and tardy 2018 was. What a disgrace of a year but I am far more comfortable with where we are heading now.

Where's the added bonus of the anti microbial stuff ? Our european CMO has to earn his wage sooner or later.